Monopar Therapeutics Inc [NASDAQ: MNPR] gained 64.58% or 1.55 points to close at $3.95 with a heavy trading volume of 40883007 shares.
The daily chart for MNPR points out that the company has recorded 5.04% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 59.52K shares, MNPR reached to a volume of 40883007 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Monopar Therapeutics Inc [MNPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MNPR shares is $18.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MNPR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Monopar Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 28, 2021.
The Average True Range (ATR) for Monopar Therapeutics Inc is set at 0.44 The Price to Book ratio for the last quarter was 2.28, with the Price to Cash per share for the same quarter was set at 2.02.
Trading performance analysis for MNPR stock
Monopar Therapeutics Inc [MNPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 62.55. With this latest performance, MNPR shares gained by 63.22% in over the last four-week period, additionally plugging by 5.04% over the last 6 months – not to mention a rise of 35.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNPR stock in for the last two-week period is set at 74.97, with the RSI for the last a single of trading hit 84.46, and the three-weeks RSI is set at 67.37 for Monopar Therapeutics Inc [MNPR]. The present Moving Average for the last 50 days of trading for this stock 2.97, while it was recorded at 2.72 for the last single week of trading, and 3.00 for the last 200 days.
Monopar Therapeutics Inc [MNPR]: A deeper dive into fundamental analysis
Monopar Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.59 and a Current Ratio set at 6.59.
An analysis of Institutional ownership at Monopar Therapeutics Inc [MNPR]
There are presently around $2.38%, or 5.09%% of MNPR stock, in the hands of institutional investors. The top three institutional holders of MNPR stocks are: MILLENNIUM MANAGEMENT LLC with ownership of 0.19 million shares, which is approximately 1.2159%. GEODE CAPITAL MANAGEMENT, LLC, holding 60036.0 shares of the stock with an approximate value of $$44906.0 in MNPR stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $$34357.0 in MNPR stock with ownership which is approximately 0.2945%.
